BCT 1801 / ABCSG 50 (BRCA-P)

BCT Study Chair:

Geoffrey Lindeman

BRCA-P is a world-first trial that aims to prevent breast cancer in women with a BRCA1 gene mutation.

The BRCA-P Clinical Trial

At least one in 400 women in the developed world carries the hereditary BRCA1 gene mutation. This mutation is associated with approximately 70% risk of developing breast cancer and 40% risk of developing ovarian cancer, over the course of a lifetime.

The current risk management for BRCA1 mutation carriers is limited to regular surveillance (MRI, mammogram, ultrasound, breast examination) or to have both healthy breasts surgically removed. Surgical removal of the ovaries is also an option for prevention of ovarian and breast cancer.

The BRCA-P study will investigate if using Denosumab is a safe and effective option for preventing breast cancer in women with a BRCA1 mutation.

Denosumab is an antibody that switches off a molecule called RANK ligand. It is currently used to strengthen the bones of people with osteoporosis (weak bones) and reduce bone complications for women whose breast cancer has spread to bone. Recent studies suggest that switching off RANK ligand with Denosumab can also inhibit the cells that cause breast cancer in women with a BRCA1 mutation. Denosumab has not been approved as a prevention medication for people with a BRCA1 gene mutation.

BRCA-P is an international breast cancer prevention clinical trial open to women with a confirmed BRCA1 gene mutation who have not had their breasts surgically removed.

Participants on BRCA-P will receive a study medication injection (Denosumab or placebo) every 6 months for 5 years. This study is a randomised, double-blind, placebo-controlled study, which means participants, and their study doctor, will not know if they are receiving the Denosumab or placebo (a treatment that looks just like the active medication, but has no effect).

In addition to exploring its use for breast cancer prevention, BRCA-P will investigate whether Denosumab decreases the risk of developing ovarian cancer or other types of cancers. The study will also assess its effect on bone health, patient reported outcomes, side effects and biological markers.

BRCA-P will be managed in Australia by Breast Cancer Trials in partnership with the Austrian Breast & Colorectal Cancer Study Group (ABCSG). It will include 2918 women from 7 countries, including approximately 300 women from Australia.

The trial is open at 15 hospitals in Australia.

If you are a woman between 25 and 55, with a known BRCA1 gene mutation, no current or previous breast cancer diagnosis, and not planning to have, or have not already completed surgery to remove both breasts, this trial might be suitable for you.

Please discuss with your General Practitioner, your High-Risk Clinic or Familial Cancer Centre team. To receive updates regarding the trial, including when new sites open to participation, please register your interest below, or visit Breastolution.

breast cancer trials geoff lindeman 9245 | 1

Professor Geoff Lindeman is the BCT Study Chair of the BRCA-P Clinical Trial.



"*" indicates required fields


Frequently Asked Questions

  • What is the aim of the BRCA-P clinical trial?

    The Breast Cancer Trials BRCA-P clinical trial is testing the effectiveness of using a drug called Denosumab to decrease or prevent the risk of developing breast cancer in women who carry a BRCA1 gene mutation.

    Breast Cancer Trials is a group of world-leading breast cancer doctors and researchers based in Australia and New Zealand with a commitment to exploring and finding better treatments for people affected by breast cancer through clinical trials research.

    Denosumab is an antibody that neutralises a molecule called RANK ligand. Switching off RANK ligand with Denosumab has been shown in other research to strengthen bone function for people with weak bones (osteoporosis) and to improve outcomes for women whose breast cancer has spread to the bone.

    Recent laboratory studies suggest that switching off RANK ligand with Denosumab could also target the culprit cell that gives rise to breast cancer in women with the BRCA1 gene mutation. The BRCA1gene mutation has been shown in the laboratory to result in a hypersensitive signalling pathway involving RANK ligand. Denosumab may be able to switch this pathway off.

    Denosumab is approved in Australia for the treatment of osteoporosis in postmenopausal people and for the prevention of bone-related problems in adults with bone metastases due to cancer.

    The BRCA-P prevention clinical trial has been fast-tracked from the laboratory because of the very positive pre-clinical data seen and because a Phase III clinical trial can provide the large numbers of participants needed to find out if it is effective in the shortest timeframe.

    Currently, many women with a BRCA gene mutation undertake preventative measures to prevent breast and ovarian cancer, including the surgical removal of their breasts and ovaries. The BRCA-P clinical trial hopes to offer these women another prevention option.

  • What is a BRCA1 or BRCA2 gene mutation?

    Most inherited cases of breast cancer are associated with mutations in one of two genes:

    • BRCA1 (BReast CAncer gene 1), and
    • BRCA2 (BReast CAncer gene 2)

    Everyone has BRCA1 and BRCA2 genes. The function of the BRCA genes is to repair DNA damage in a cell and keep breast, ovarian, and other cells growing normally. An inherited mutation in a BRCA1 or BRCA2 gene means that one of the copies of the gene is not working but that the other copy can maintain the normal function. It is when the second copy of the BRCA1 or BRCA2 gene acquires a mutation that both copies are now non-functional, and the wrong protein is made.

    With two non-functional copies making the wrong protein, the ability of the cell to repair DNA damage is affected. If DNA damage cannot be repaired, but the cell remains alive, the cell may become cancerous by growing uncontrollably and forming a tumour mass.

    BRCA1 and BRCA2 gene mutations account for about 5-10% of breast cancer diagnoses in Australia today.

  • Who can this affect?

    Breast cancers associated with a BRCA1 or BRCA2 gene mutation tend to develop in younger women where the incidence becomes significant in their 30s and 40s.

    You are more likely to have a genetic mutation linked to breast cancer if:

    • You have blood relatives (grandmothers, mother, sisters, aunts) on either your mother’s or father’s side of the family who had breast cancer diagnosed before age 40.
    • There is both breast and ovarian cancer on the same side of the family or in a single individual.
    • You have a relative(s) with triple-negative breast cancer diagnosed before age 50.
    • There are other cancers in your family in addition to breast or ovarian cancer, such as prostate, melanoma or pancreatic cancer.
    • Women in your family have had cancer in both breasts.
    • You are of Ashkenazi Jewish (Eastern European) heritage.
    • A man in your family has had breast cancer.
    • There is a known abnormal breast cancer gene in your family.

    If you think you are at high risk for a genetic mutation linked to breast cancer, see your doctor.

    Usually, the first person to be tested for a mutation is the person who has been affect by cancer, and if a mutation is found in that person, other family members can be tested.

  • What is the risk of breast cancer for women with a BRCA1 or BRCA2 gene mutation?

    It is estimated that in Australia today, about 1 in 400 women are at the highest risk of breast cancer because they carry a BRCA1 or BRCA2 gene mutation. For these people, carrying a gene mutation is associated with an approximate 70% risk of developing breast cancer over the course of their lifetime. And they can have a risk of up to 40% of developing ovarian cancer.

    Many of those at this highest risk of breast cancer will not be aware they carry a breast cancer gene mutation until they are diagnosed with breast cancer themselves or a close family member is diagnosed. Each of them will have the potential to pass this inherited gene mutation to their children.

    Jewish women of eastern European ancestry (Ashkenazi) are more likely to carry a BRCA1 or BRCA2 gene mutation, estimated to be present in about 1 in 40 women. This is 20 times more common than in the general population.

  • How will the trial be conducted?

    The BRCA-P trial will be led internationally by our colleagues at the Austrian Breast Cancer Study Group and conducted in Australia by Breast Cancer Trials (BCT). Professor Geoffrey Lindeman is the BCT Study Chair of the trial and the global co-Principal Investigator.

    Throughout Australia, 15 sites will be open to patient recruitment together with six other countries including Austria, Germany, Israel, Spain, the United Kingdom and the United States.

    The international recruitment target is 2,918 participants and Australia will recruit 300 participants over a two-year period. The trial will include five years of active treatment comprising six monthly injections of the drug together with annual follow ups and required tests. Participants will be followed up every 12 months for a further five years of post-treatment assessment.

    The trial will be a randomised, double-blind, placebo-controlled study meaning that participants will be randomly allocated to receive either the trial drug or a placebo and neither the participant nor their doctor will know who is on the study drug and who is receiving the placebo. This will ensure the trial results and reporting will be unaffected by any potential bias.

  • Who can participate in this clinical trial?

    The BRCA-P clinical trial is a prevention clinical trial, therefore potential participants are those who have not had breast cancer but who carry the BRCA1 gene mutation and therefore are at higher risk.

    Eligibility must be assessed carefully and includes the following criteria:

    • Women who carry a BRCA1 gene mutation and are aged 25-55 years and unaffected by breast or ovarian cancer.
    • May be either pre or post-menopausal.
    • Not pregnant or planning to get pregnant.
    • Have not had preventative breast surgery.
    • Not taking any breast cancer preventative agents such as Tamoxifen or an Aromatase Inhibitor.
  • Why is it only for people with the BRCA1 gene mutation?

    The pre-clinical evidence supports potential activity for denosumab in women with a faulty BRCA1 gene. There is not sufficient data to as yet to support a clinical trial in other high-risk women, such as those with a BRCA2 mutation.

  • Why is there an age limit on this clinical trial?

    The annual incidence of breast cancer is highest in their 30-50’s for women with a faulty BRCA1 gene so the study is focussing on this group of women in order to see if the incidence of breast cancers can be reduced. There is also strong pre-clinical evidence to support the evaluation of denosumab in pre-menopausal women.

  • Why can only women participate in this clinical trial?

    Although the relative risk of developing male breast cancer is high for BRCA1 mutation carriers compared to men without a faulty gene, the absolute risk of breast cancer in men is low (~1.2% to age 70; JNCI 2007).

    Put another way, male breast cancer in BRCA1 mutation carriers is rare, by comparison the average lifetime risk of breast cancer for a healthy woman is ~12.5%.

    We would have to increase the size of the study to treat thousands of men, with very little (if any) benefit seen in the vast majority. Inclusion of male subjects is not therefore feasible. However, if we do see a benefit for women, this could be addressed in men.

  • Where can I participate?

    The BRCA-P clinical trial will be open by Breast Cancer Trials in 15 medical institutions throughout Australia.
    The BRCA-P trial will open at:
    • The Olivia Newton John Cancer Wellness and Research Centre (Austin Hospital)
    • Ballarat Oncology and Haematology Services
    • Concord Repatriation General Hospital
    • Lake Macquarie Private Hospital
    • Monash Medical Centre (Clayton)
    • Prince of Wales Hospital
    • Royal Adelaide Hospital
    • Royal Brisbane and Women’s Hospital
    • Royal Hobart Hospital
    • The Royal Melbourne Hospital
    • Royal North Shore Hospital
    • St John of God Hospital Subiaco
    • St Vincent’s Hospital Sydney
    • Westmead Hospital
    • Wollongong Hospital
  • I have a strong family history of breast cancer. How do I find out if I have a BRCA gene mutation?

    Genetic testing is often offered to women who are diagnosed with breast cancer at an early age (35 and under), who have a strong family history or who are diagnosed with certain types of breast cancer such as ‘triple negative breast cancer’.
    If a gene mutation such as in BRCA1 or BRCA2 (the most common types) is identified, this can be associated with a family history of breast, ovarian, prostate and some other types of cancer. It is important to note that family history can come from your mother or father’s side of the family.
    Genetic testing is offered only through a Familial cancer clinic. If a woman is referred to a Familial cancer clinic, the availability, limitations, potential benefits, and possible consequences of genetic testing will be discussed with her. If you are concerned about your strong family history of breast cancer, or you have a close family member with a BRCA gene mutation, speak with your doctor about a referral to a family cancer clinic.
    Remember, having a BRCA1 or BRCA2 gene mutation doesn’t mean you will be diagnosed with breast cancer and if one family member has a genetic mutation linked to breast cancer, it does not mean that all family members will have it.
  • Will this research help to prevent other cancers as well?

    The BRCA-P clinical trial may also lead to significant information related to the treatment of ovarian cancer, other types of cancer and bone related issues such as osteoporosis. In this way, the results of one clinical trial may affect many thousands of people across different areas of medical research and community concern.

  • How can I help?

    Breast Cancer Trials understands that what is learned from this prevention trial will be very important to many people, in particular individuals and families who carry the BRCA1 gene mutation.
    If you think you meet the eligibility criteria for the BRCA-P clinical trial, please speak with your Familial Cancer Centre or GP about referral to a site that is participating in the BRCA-P clinical trial.
    The BRCA-P clinical trial will cost about $7.5 million to conduct in Australia. The National Health and Medical Research Council has supported the trial with a peer-reviewed grant of $2.8 million, indicating the value of this research to the long-term health of Australians.
    However, more funding is needed to ensure this important research is conducted.
    If you can help, please make a donation to the trial here. By joining our Regular Giving Program and committing to a monthly gift, you’ll be investing in a brighter future for our families and loved ones.
    If you’d like to be kept informed about the BRCA-P clinical trial and its progress, please get in touch through our BRCA-P Enquiries page.
    If you’d like to keep up to date about all of Breast Cancer Trials life-saving research, you can subscribe to the Breast Cancer Trials Podcast, or follow us on Facebook, YouTube, Twitter, LinkedIn and Instagram.

Look up the contact details for your nearest BRCA-P participating institution.

Register your interest in participating in the BRCA-P clinical trial

Early Breast Cancer